Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
Business Wire•29/09/2026•07:30 ET
0
Key Highlights
- ➤ARWR schedules October 14 webinar featuring interim ARO-MAPT Phase 1/2a data
- ➤ARO-MAPT targets MAPT gene silencing for Alzheimer’s and other tauopathies
- ➤AROMAPT-SC-1001 plans enrollment of up to 64 healthy volunteers and 48 early Alzheimer’s subjects
- ➤ARO-MAPT uses subcutaneous dosing and Arrowhead’s TRiM™ CNS delivery platform
Expert Statements
Adam Boxer, Endowed Professor in Memory and Aging, UCSF
“Silencing MAPT in Alzheimer’s Disease and other Tauopathies”
James Hamilton, M.D., MBA, Arrowhead Pharmaceuticals
“Interim Results from ARO-MAPT Phase 1/2a Study”
Arrowhead Pharmaceuticals to Host a Webinar with Interim Clinical Data from a Phase 1/2a Study of ARO-MAPT for the Treatment of Alzheimer’s Disease and Other Tauopathies
– ARO-MAPT utilizes the Targeted RNAi Molecule (TRiM™) platform designed for subcutaneous administration and systemic delivery to the CNS by crossing the blood-brain barrier –
Get started
Create a free account to read the full story.